PEG filgrastim [SD-01] appears to have `therapeutic advantages' over filgrastim in patients receiving chemotherapy for non-small-cell lung cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1249, 2000-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sunitinib appears to be an effective single-agent therapy for patients with recurrent non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1626, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Advances in chemotherapy in advanced non-small-cell lung cancer

By Maione Paolo   Rossi Antonio   Sacco Paola Claudia   Bareschino Maria Anna   Schettino Clorinda   Gridelli Cesare  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 18, 2010-12 ,pp. : 2997-3007

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?

By Giovannetti Elisa   Toffalorio Francesca   De Pas Tommaso   Peters Godefridus J  

Pharmacogenomics, Vol. 13, Iss. 9, 2012-07 ,pp. : 1073-1086

Future Medicine

Access to resources Recommend Favorite

Tegafur/uracil in combination with cisplatin appears to be active in advanced non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1626, 2008-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Chemotherapy of Non-small Cell Lung Cancer in Elderly Patients

By  

Current Medicinal Chemistry, Vol. 9, Iss. 16, 2002-08 ,pp. : 1487-1495

Bentham Science Publishers

Access to resources Recommend Favorite